Copy Link Print Information

RANKL/TNFSF11 Protein, Human (HEK293)

4 Cited Publications
Customer Review

Based on 4 publication(s) in Google Scholar

RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293) is a recombinant human RANKL (G64-D245) without any tag, which is produced in HEK293 cell.

For research use only. We do not sell to patients.
  • Species: Human
  • Source: HEK293
  • Storage:
    Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • RANKL/TNFSF11 Protein, Human (HEK293) Product Image
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • RANKL/TNFSF11 Protein, Human (HEK293) Product Image
Size
Price
Stock
Quantity
Amount: USD 0.00
Please select quantity
or
or

* Please select Quantity before adding items.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Service
Data Download

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Find Your Local Distributor Your local distributor: Hycultec GmbHHycultec
  • Biological Activity
  • Technical Parameters
  • Product Properties
  • Documentation
  • References
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Biological Activity

Description

RANKL (TNFSF11), a type II transmembrane protein, is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of RANK. When binding to RANK, it induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs). RANKL/TNFSF11 Protein, Human (HEK293) is a recombinant human RANKL (G64-D245) without any tag, which is produced in HEK293 cell[1][2].

Background

RANKL (TNFSF11) belongs to TNF family. RANKL is a type II transmembrane protein and is a receptor activator of NF-κB (RANK) ligand. RANKL is an activator of NF-κB. RANKL binds to NF-κB and induces the differentiation of monocyte/macrophage-lineage cells into osteoclasts and leads to osteoclast precursor maturation. In bone tissue, RANKL is expressed by osteoblasts, osteocytes and immune cells, especially in osteoblasts and osteocytes[1]. RANKL is also expressed by T cells and increases proliferation and survival of dendritic cells[2].
Human RANKL shares 82.02% and 84.44% common aa identity with mouse and rat respectively. Human RANKL consists of cytoplasmic domain (1-47), helical domain (48-68), and extracellular domain (69-317). The soluble chain (140-317) is released when cleaved by enzymes such as matrix metalloproteinases (MMP3 or 7) and ADAM[1][3].
RANKL is critical for osteoclasts maturation, bone modeling, and bone remodeling, as well as the development of lymph nodes (LNs)[1].

In Vitro

RANKL (human, -5 ng/mL, 24 h) stimulates migration of a clear cell RCC cell line, Caki-1[4].
RANKL (human, 24 h) stimulates PAa cell migration and invasion[5].

In Vivo

RANKL (human, .4 or 2 mg/kg/day, s.c.) induces high bone turnover and decreases bone volume, density, and strength in C57BL/6J female mice[6].

Verified Bioactivity

1.Immobilized human TNFSF11 at 2 μg/mL (100 μL/well) can bind human Osteoprotegerin-hFc and the EC50 is 5-40 ng/mL.
2. Measured by its ability to induce TRAP activity, inducing osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells. The ED50 for this effect is < 20 ng/mL.
3. Loaded Narlumosbart (HY-P99966) on AHC2 biosensor, can bind RANKL/TNFSF11 Protein, Human (HEK293) with an affinity constant of <1.000E-11 M as determined in BLI assay.

Results
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
    Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells. The ED50 for this effect is 19.69 ng/mL, corresponding to a specific activity is 5.079×104 units/mg.
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
    Loaded Narlumosbart (HY-P99966) on AHC2 biosensor, can bind RANKL/TNFSF11 Protein, Human (HEK293) with an affinity constant of <1.000E-11 M as determined in BLI assay.

Technical Parameters

  • Species Human
  • Source HEK293
  • Tag Tag Free
  • Accession

    AAC51762.1 (G64-D245)

  • Gene ID
    8600  [NCBI]
  • Molecular Construction
    • N-term
    • RANKL (G64-D245)
      Accession # AAC51762.1
    • C-term
  • Protein Length

    Partial

  • Synonyms

    Tumor necrosis factor ligand superfamily member 11; RANKL; CD254; ODF; OPGL; TNFSF11; TRANCE

  • AA Sequence

    GSQHIRAEKAMVDGSWLDLAKRSKLEAQPFAHLTINATDIPSGSHKVSLSSWYHDRGWGKISNMTFSNGKLIVNQDGFYYLYANICFRHHETSGDLATEYLQLMVYVTKTSIKIPSSHTLMKGGSTKYWSGNSEFHFYSINVGGFFKLRSGEEISIEVSNPSLLDPDQDATYFGAFKVRDID

  • Predicted Molecular Mass

    20.5 kDa

  • Molecular Weight

    Approximately 27-33 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

  • Glycosylation

    Yes

  • Purity

    ≥ 90%, as determined by reducing SDS-PAGE.

Product Properties

Appearance

Lyophilized powder

Formulation

1.Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4, 5% trehalose, 5% mannitol, 0.01% Tween 80.
2.Lyophilized from a 0.22 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4.
Please refer to the lot-specific COA for specific buffer information.

Endotoxin Level

<1 EU/μg, determined by LAL method.

Reconstitution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

References

[1]. Ono T, et al. RANKL biology: bone metabolism, the immune system, and beyond. Inflamm Regen. 2020 Feb 7;40:2. [Content Brief]

[2]. Li B, et al. Roles of the RANKL-RANK Axis in Immunity-Implications for Pathogenesis and Treatment of Bone Metastasis. Front Immunol. 2022 Mar 21;13:824117. [Content Brief]

[3]. Tobeiha M, et al. RANKL/RANK/OPG Pathway: A Mechanism Involved in Exercise-Induced Bone Remodeling. Biomed Res Int. 2020 Feb 19;2020:6910312. [Content Brief]

[4]. Mikami S, et al. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas. J Pathol. 2009 Aug;218(4):530-9. [Content Brief]

[5]. Peng X, et al. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS One. 2013;8(3):e58361. [Content Brief]

[6]. Lloyd SA, et al. Soluble RANKL induces high bone turnover and decreases bone volume, density, and strength in mice. Calcif Tissue Int. 2008 May;82(5):361-72. [Content Brief]

View More

Calculators

Reconstitution Calculator

Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration

Volume (to add to vial)
=
Mass (in vial)
÷
Desired Reconstitution Concentration
Dilution Calculator

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

Concentration (start)
×
Volume (start)
=
Concentration (final)
×
Volume (final)
The Specific Activity Calculator Equation
  • Specific Activity (Unit/mg)
  • Biological Activity (ED50)

Specific Activity (Unit/mg) = 106 ÷ Biological Activity (ED50)

Specific Activity (Unit/mg)
Unit/mg
= 106 ÷
Biological Activity (ED50)
106 ÷
ng/mL

RANKL/TNFSF11 Protein, Human (HEK293) Related Classifications

Measured by its ability to inhibit anti-CD3-induced proliferation of stimulated CTLL-2 mouse cytotoxic T cells. The ED50 this effect is 0.8023 μg/ml, corresponding to a specific activity is 1246.42 units/mg.

  • Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells. The ED50 for this effect is 19.69 ng/mL, corresponding to a specific activity is 5.079×104 units/mg.

  • Loaded Narlumosbart (HY-P99966) on AHC2 biosensor, can bind RANKL/TNFSF11 Protein, Human (HEK293) with an affinity constant of <1.000E-11 M as determined in BLI assay.

Assay Types
  • 1/16

    MedChemExpress Validation
     Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells. The ED50 for this effect is 19.69 ng/mL, corresponding to a specific activity is 5.079×104 units/mg.

  • 1/16

    MedChemExpress Validation
     Loaded Narlumosbart (HY-P99966) on AHC2 biosensor, can bind RANKL/TNFSF11 Protein, Human (HEK293) with an affinity constant of <1.000E-11 M as determined in BLI assay.

  • 1/16

    RANKL/TNFSF11 Protein, Human (HEK293) purchased from MedChemExpress. Usage Cited in: Dev Cell. 2025 Sep 3:S1534-5807(25)00530-1. [Abstract]

    Customer Validation
     The luciferase activities of NF-κB and CREB1 reporter genes in A549 and NCIH1299 lung cancer cells and 143B osteosarcoma following treating with RANKL/TNFSF11 Protein, Human (HEK293) (TNFSF11, 5 ng/mL, 24 h) in the presence or absence of WT-rhTR11B (5 ng/mL, 24 h).

  • 1/16

    RANKL/TNFSF11 Protein, Human (HEK293) purchased from MedChemExpress. Usage Cited in: Dev Cell. 2025 Sep 3:S1534-5807(25)00530-1. [Abstract]

    Customer Validation
     The interaction between extracellular TNFSF11 and TR11B in the culture media of A549 cells treated with or without RANKL/TNFSF11 Protein, Human (HEK293) (TNFSF11, 5 ng/mL; 24 h), in the presence or absence of Heparinase (5 U/mL). TR11B was immunoprecipitated by anti-TR11B antibodies. Extracellular TR11B, TNFSF11, and SDC1were measured by ELISA.

  • 1/16

    RANKL/TNFSF11 Protein, Human (HEK293) purchased from MedChemExpress. Usage Cited in: Arab J Chem. 2023 Aug, 104888.

    Customer Validation
     RAW 264.7 cells were cultured in a-MEM containing RANKL/TNFSF11 Protein, Human (HEK293) (RANKL, 50 ng/mL) for 120 h. The CCK-8 assay was used to detect proliferation.

  • RANKL/TNFSF11 Protein, Human (HEK293) Product Image
    1/16
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • Experimental Validation Results for RANKL/TNFSF11 Protein, Human (HEK293)
  • RANKL/TNFSF11 Protein, Human (HEK293) Product Image

  • RANKL/TNFSF11 Protein, Human (HEK293) purchased from MedChemExpress. Usage Cited in: Dev Cell. 2025 Sep 3:S1534-5807(25)00530-1. [Abstract]

    The luciferase activities of NF-κB and CREB1 reporter genes in A549 and NCIH1299 lung cancer cells and 143B osteosarcoma following treating with RANKL/TNFSF11 Protein, Human (HEK293) (TNFSF11, 5 ng/mL, 24 h) in the presence or absence of WT-rhTR11B (5 ng/mL, 24 h).

  • RANKL/TNFSF11 Protein, Human (HEK293) purchased from MedChemExpress. Usage Cited in: Dev Cell. 2025 Sep 3:S1534-5807(25)00530-1. [Abstract]

    The interaction between extracellular TNFSF11 and TR11B in the culture media of A549 cells treated with or without RANKL/TNFSF11 Protein, Human (HEK293) (TNFSF11, 5 ng/mL; 24 h), in the presence or absence of Heparinase (5 U/mL). TR11B was immunoprecipitated by anti-TR11B antibodies. Extracellular TR11B, TNFSF11, and SDC1were measured by ELISA.

  • RANKL/TNFSF11 Protein, Human (HEK293) purchased from MedChemExpress. Usage Cited in: Arab J Chem. 2023 Aug, 104888.

    RAW 264.7 cells were cultured in a-MEM containing RANKL/TNFSF11 Protein, Human (HEK293) (RANKL, 50 ng/mL) for 120 h. The CCK-8 assay was used to detect proliferation.